Are PROMs sufficient to record late outcome of breast cancer patients treated with radiotherapy? A comparison between patient and clinician reported outcome through an outpatient clinic after 10 years of follow up

Brouwers, P.J.A.M.; Loon, J. Van; Houben, Ruud; Paulissen, J.; Engelen, Sanne; Heuts, M. J.; Boer, Maaike de; Verhoeven, K.; Ruysscher, Dirk De; Boersma, Liesbeth

doi:10.1016/j.radonc.2017.08.004

Cited by 16 publications

(19 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The median sample size was 1029 (range, 20–4451). Of the nine studies, five [ [15] , [16] , [17] , [18] , [19] ] reported the tumour histology, eight [ 5 , 7 , 15 , [17] , [18] , [19] , [20] , [21] ] reported on surgery type and five [ 5 , [15] , [16] , [17] , 20 ] reported treatment with systemic therapies. All patients received external beam RT.…”

Section: Resultsmentioning

confidence: 99%

“…[ 18 ] 4.5 years Mild/Mod RTOG/EORTC CRO 37 NS 11 NS NS NS NS 7 PRO 39 NS 3 NS NS NS NS 5 Brouwers et al. [ 20 ] 10 years Any/Mod/Sev CTCAE CRO 243 (211 a ) 120 20 NS NS 44 NS NS PRO 332 (283 a ) 137 98 NS NS 85 NS NS Azoury et al. [ 19 ] 2 years Mod/Sev HBCS CRO 25 6 NS 4 3 NS NS NS PRO 25 8 NS 2 ...…”

Section: Resultsunclassified

“…CROs were documented by physicians in all studies except two [ 20 , 21 ], where the CRO was documented by a physician and a trained breast research radiographer or a physician and trial physician assistant. Digital photographs were taken in four studies [ 5 , 15 , 19 , 21 ] at various time-points post-RT.…”

Section: Resultsmentioning

confidence: 99%

“…The skin assessment tools used by clinicians included four-point Likert scales (n = 4) [ 5 , 15 , 16 , 21 ] where responses were graded as none/mild/moderate/severe or none/a little/quite a bit/very much, the CTCAE (n = 3) [ 7 , 17 , 20 ], Harvard Breast Cosmesis Scale (HBCS; n = 1) [ 19 ], Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC; n = 1) and. These are summarized in Appendix B .…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

A systematic review and meta-analysis of clinician-reported versus patient-reported outcomes of radiation dermatitis

et al. 2020

View full text Add to dashboard Cite

Radiation dermatitis is a common adverse effect of radiotherapy (RT) in breast cancer patients. Although radiation dermatitis is reported by either the clinician or the patient, previous studies have shown disagreement between clinician-reported outcomes (CROs) and patient-reported outcomes (PROs). This review evaluated the extent of discordance between CROs and PROs for radiation dermatitis. Studies reporting both clinician and patient-reported outcomes for external beam RT were eligible. Nine studies met the inclusion criteria for the systematic review, while 8 of these studies were eligible for inclusion in a meta-analysis of acute and late skin toxicities. We found an overall agreement between CROs and PROs of acute skin colour change, fibrosis and/or retraction, and moist desquamation ( p > 0.005). Reporting of late breast pain, breast edema, skin colour change, telangiectasia, fibrosis and/or retraction and induration/fibrosis alone ( p > 0.005) were also in agreement between clinicians and patients. Our meta-analysis revealed a greater reporting of acute breast pain by patients (RR = 0.89, 95% CI 0.87–0.92, p < 0.001), greater reporting of acute breast edema by physicians (RR = 1.80, 95% CI 1.65–1.97, p < 0.001) and a greater reporting of late breast shrinkage by patients (RR = 0.61, 95% CI 0.44–0.86, p = 0.005). However, our review was limited by the discrepancies between PRO and CRO measurement tools as well as the absence of standard time points for evaluation of radiation dermatitis. Given potential discrepancies between CROs and PROs, both measures should be reported in future studies. Ultimately, we advocate for the development of a single tool to assess symptoms from both perspectives.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsunclassified

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

A systematic review and meta-analysis of clinician-reported versus patient-reported outcomes of radiation dermatitis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…PROMs are subjective measurements that may enable reliable analyses of postoperative QoL and general satisfaction from the patient’s perspective rather than from the surgeon’s 22. PROMs can be used to identify patients who experience a heavy burden of side effects, requiring specific attention 41. A systematic review of 24 unique controlled trials showed PROMs are associated with improved symptom control, increased supportive care measures and patient satisfaction, and the routine use of PROMs increases the frequency of discussion of patient outcomes during consultations 42.…”

Section: Discussionmentioning

confidence: 99%

Chinese multicentre prospective registry of breast cancer patient-reported outcome-reconstruction and oncoplastic cohort (PRO-ROC): a study protocol

Yang

et al. 2019

BMJ Open

View full text Add to dashboard Cite

IntroductionAvailable patient-reported outcome (PRO) studies are mainly from single institution or of small sample size, and the variations across hospitals and regions were not fully analysed. A multicentre, prospective, patient-reported outcome-reconstruction and oncoplastic cohort (PRO-ROC) will be planned to assess the PROs of Chinese patients with breast cancer who will undergo breast reconstruction (BR) or oncoplastic breast-conserving surgery (OBCS).Methods and analysisThe inclusion criteria are female patients with breast cancer aged >18 years old who will undergo BR or OBCS. This cohort will include at least 10 000 consecutive patients (about 5000 patients who will undergo BR and 5000 patients who will undergo OBCS). The exposures were surgery types: BR and OBCS regardless of the techniques and materials used. The primary endpoint will be PROs, which include BREAST-Q and quality of life (European Organisation for Research and Treatment (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) and EORTC QoL Breast Cancer-specific version (QLQ-BR23)). All patients will be followed up to 24 months after operations. All data will be prospectively collected using an app software. Data will be analysed using SPSS and Stata software.Ethics and disseminationThis study follows the Helsinki Declaration. All patients will be asked to sign an informed consent before enrolment. The results of this study will be presented at national and international meetings and published in a scientific peer-reviewed journal.Trial registration numberNCT04030845.

show abstract

Follow-up Guidelines, Evidence, and Recommendations

Kimman

Hezewijk

Boersma

2022

Breast Cancer Radiation Therapy

View full text Add to dashboard Cite

Are PROMs sufficient to record late outcome of breast cancer patients treated with radiotherapy? A comparison between patient and clinician reported outcome through an outpatient clinic after 10 years of follow up

Cited by 16 publications

References 17 publications

A systematic review and meta-analysis of clinician-reported versus patient-reported outcomes of radiation dermatitis

A systematic review and meta-analysis of clinician-reported versus patient-reported outcomes of radiation dermatitis

Chinese multicentre prospective registry of breast cancer patient-reported outcome-reconstruction and oncoplastic cohort (PRO-ROC): a study protocol

Follow-up Guidelines, Evidence, and Recommendations

Contact Info

Product

Resources

About